文献速递心脑血管急症重症综合管理与镇静镇痛

Nelonemdaz治疗院外心脏骤停患者:一项随机临床试验

Nelonemdaz Treatment for Patients With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial.
PubMed 文献 · Crit Care Med · 2025-01-14
一句话结论该项Ⅱ期试验显示,Nelonemdaz未能降低院外心脏骤停患者48-52小时血清NSE水平,高剂量组脑MRI各向异性分数较高,提示白质损伤较少。

这是一项在韩国5个中心开展的双盲、安慰剂对照、随机、多中心Ⅱ期试验,纳入105例接受目标温度管理的院外心脏骤停患者,按1:1:1随机分为高剂量组(5250 mg,n=37)、低剂量组(3250 mg,n=35)和安慰剂组(n=33)。主要终点48-52小时血清NSE水平在三组间无差异(高剂量组中位数23.7 vs 安慰剂组17.5,低剂量组26.6 vs 安慰剂组,均p>0.05)。高剂量组脑MRI各向异性分数显著高于安慰剂组(0.465 vs 0.441,p=0.028),低剂量组与安慰剂组无差异(p>0.05)。第90天改良Rankin量表有利偏移的common OR在高剂量组为1.25(0.48-3.24)、低剂量组为1.22(0.47-3.20),均p>0.05。未报告严重不良事件。

要点

  • 在105例院外心脏骤停且接受目标温度管理的患者中,Nelonemdaz高剂量(5250 mg)和低剂量(3250 mg)均未降低48-52小时血清NSE水平(与安慰剂组比较均p>0.05)。
  • 高剂量组脑MRI各向异性分数显著高于安慰剂组(0.465,0.449-0.485 vs 0.441,0.431-0.464;p=0.028),低剂量组与安慰剂组无差异(p>0.05)。
  • 第90天改良Rankin量表有利偏移的common OR在高剂量组为1.25(95%CI 0.48-3.24)、低剂量组为1.22(95%CI 0.47-3.20),与安慰剂组比较均p>0.05。
  • 该试验未报告严重不良事件。
  • 主要终点NSE在93例患者中评估,三组间均无显著差异。

适用人群与场景

  • 院外心脏骤停(OHCA)并接受目标温度管理的患者,年龄中位数61岁,男性占82%。
  • 试验在韩国5个中心纳入105例患者,入组时间为2018年11月18日至2023年2月23日。

处置流程与药物剂量

  • 患者按1:1:1随机分配至高剂量Nelonemdaz 5250 mg组(n=37)、低剂量Nelonemdaz 3250 mg组(n=35)或安慰剂组(n=33)。

研究设计与关键结果

  • 研究设计:双盲、安慰剂对照、随机、多中心Ⅱ期试验,在韩国5个中心纳入105例OHCA并接受目标温度管理的患者。
  • 主要终点:48-52小时血清神经元特异性烯醇化酶(NSE)水平,在93例患者中评估;高剂量组中位数23.7(四分位距15.0-69.9)vs 安慰剂组17.5(13.6-113.0),低剂量组26.6(16.2-83.4)vs 安慰剂组,均p>0.05。
  • 脑MRI各向异性分数:高剂量组0.465(0.449-0.485)vs 安慰剂组0.441(0.431-0.464),p=0.028;低剂量组0.462(0.439-0.480)vs 安慰剂组,p>0.05。
  • 第90天改良Rankin量表有利偏移的common OR:高剂量组1.25(95%CI 0.48-3.24),低剂量组1.22(95%CI 0.47-3.20),与安慰剂组比较均p>0.05。
  • 未报告严重不良事件。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照、多中心Ⅱ期临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论为Nelonemdaz治疗未降低OHCA患者血清NSE水平;高剂量组脑MRI各向异性分数较高,提示脑白质损伤较少。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Nelonemdaz is a N -methyl d -aspartate receptor subtype 2B-selective N-methyl-D-aspartate receptor antagonist and a potent free-radical scavenger that might ameliorate hypoxic-ischemic brain injury after out-of-hospital cardiac arrest (OHCA). We investigated the efficacy of nelonemdaz for patients with OHCA.

DESIGN: A double-blind, placebo-controlled, randomized, multicenter phase II trial.

SETTING: This trial enrolled 105 patients at five sites in South Korea between November 18, 2018, and February 23, 2023.

PARTICIPANTS: OHCA patients undergoing targeted temperature management.

INTERVENTIONS: Patients were randomly assigned to high-dose (5250 mg), low-dose (3250 mg), and placebo groups at a 1:1:1 ratio.

MEASUREMENTS AND MAIN RESULTS: Patients with a median age of 61 years (82% male) were assigned to the high-dose ( n = 37), low-dose ( n = 35), and placebo ( n = 33) groups. The primary outcome, the serum level of neuron-specific enolase (NSE) at 48-52 hours, was evaluated in 93 patients. There was no difference in serum NSE between high-dose (median and interquartile range; 23.7, 15.0-69.9) and placebo (17.5, 13.6-113.0) groups, or between low-dose (26.6, 16.2-83.4) and placebo groups ( p > 0.05). Brain MRI fractional anisotropy was significantly higher in the high-dose group compared with the placebo group (0.465, 0.449-0.485 vs. 0.441, 0.431-0.464; p = 0.028), but not between low-dose (0.462, 0.439-0.480) and placebo groups ( p > 0.05). At day 90, the common odds ratio (95% CI) indicating a numerically favorable shift in the modified Rankin Scale was 1.25 (0.48-3.24) and 1.22 (0.47-3.20) in the high-dose and low-dose groups, respectively, compared with placebo group ( p > 0.05). No serious adverse events were reported.

CONCLUSIONS: Nelonemdaz treatment of patients after OHCA did not reduce serum NSE levels compared with controls. Patients treated with high-dose nelonemdaz showed higher brain MRI fractional anisotropy suggesting less cerebral white matter damage.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Chun BJ, Yeom SR, Chung SP, et al. Nelonemdaz Treatment for Patients With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. Crit Care Med. 2025. PMID: 39899673. doi:10.1097/CCM.0000000000006579

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。